Treatment of chronically infected mice with the anti-TNF antibody infliximab resulted in an increase of LCMV-specific CD4+ and CD8+ T cells, a concomitant reduction of PD-1 expression, and enhanced antigen-specific cytotoxicity of CD8+ T cells along with an improved control of viral infection. This evidence concerns the gene CD8A and viral infectious disease.